Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00530192 · ClinicalTrials.gov registry record · Early Phase 1

Molecular Profiling Protocol (SCRI-CA-001)

A Early Phase 1 study of Refractory Cancer, sponsored by Scottsdale Healthcare.

Completed
Registry status
Early Phase 1
Development phase
86
Enrollment target
9
Study locations

NCT00530192 is a Early Phase 1 study of Refractory Cancer that has completed, run by Scottsdale Healthcare. The registered enrollment target is 86 participants, below the 125-participant average among 15 other Refractory Cancer trials with a reported enrollment target (31% lower). The trial reports 9 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00530192, a Early Phase 1 study of Refractory Cancer, has completed, sponsored by Scottsdale Healthcare.

COMPLETED
Registry status
Early Phase 1
Development phase
86 participants
Enrollment target
9
Study locations

Study Summary

This is an open-label, multicenter pilot study in patients with advanced solid tumors. The primary objective of this study is to compare progression-free survival using a treatment regimen selected by molecular profiling with progression-free survival for the most recent regimen the patient has progressed on. To be eligible, patients must have received at least two lines of prior chemotherapeutic, hormonal or biological regimens for advanced disease, have measurable or evaluable, refractory disease and have clear documentation of the time between treatment start and documented progression on the last treatment prior to study entry. Eligible patients must undergo or have available a tumor biopsy for molecular profiling within 2 months of IHC/FISH and/or DNA microarray analysis.

Conditions Studied

Refractory Cancer

Interventions

  • OTHER Treatment based on Molecular Profiling

Study Locations (9)

Arizona

  • TGen Clinical Research Services - Scottsdale
  • Mayo Clinic - Scottsdale

California

  • Tower Oncology - Beverly Hills
  • Louis Warschaw Prostate Cancer Center at Cedars Sinai Medical Center - Los Angeles

Texas

  • South Texas Oncology Hematology - San Antonio
  • Tyler Cancer Center - Tyler

Alabama

  • Oncology Specialties - Huntsville

Indiana

  • Central Indiana Cancer Center - Indianapolis

South Carolina

  • Cancer Center of the Carolinas - Greenville

Trial Details

FieldValue
Enrollment Target 86 participants
Start Date 2006-09
Est. Completion 2009-03
Phase Early Phase 1

Sponsor

Scottsdale Healthcare

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00530192

The ClinicalTrials.gov registry entry for NCT00530192 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 125-participant average among 15 other Refractory Cancer trials with a reported enrollment target (31% lower). The listed sponsor is Scottsdale Healthcare, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Refractory Cancer appearing as the primary indexed condition, and to 1 intervention - of which Treatment based on Molecular Profiling is the first listed.

NCT00530192 reports 9 study locations spanning 6 distinct geographic areas - top geographies include Arizona, California, Texas.

Frequently Asked Questions

What is clinical trial NCT00530192 about?

NCT00530192 is a clinical study titled "Molecular Profiling Protocol (SCRI-CA-001)". This is an open-label, multicenter pilot study in patients with advanced solid tumors. The primary objective of this study is to compare progression-free survival using a treatment regimen selected by molecular profiling with progression-free survival for the most recent regimen the patient has pro...

What is the current status of trial NCT00530192?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 86 participants. The study started on 2006-09. Estimated completion is 2009-03.

What conditions does trial NCT00530192 study?

This clinical trial studies the following conditions: Refractory Cancer.

What interventions are being tested in trial NCT00530192?

The interventions under investigation include: Treatment based on Molecular Profiling (OTHER).

Who is sponsoring clinical trial NCT00530192?

This trial is sponsored by Scottsdale Healthcare, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00530192 being conducted?

This trial has 9 study locations across Alabama, Arizona, California, Indiana, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Refractory Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Refractory Cancer

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.